美国食品和药物管理局批准Eversense 365, 一年期的CGM治疗1型和2型糖尿病,每年一次. FDA approves Eversense 365, a year-long CGM for Type 1 and 2 diabetes, with annual insertion.

美国食品和药物管理局批准了Eversense 365持续血糖监测 (CGM) 系统,这是该类型的首款全年可使用的设备,适用于1型和2型糖尿病的成年人. The FDA has approved the Eversense 365 continuous glucose monitoring (CGM) system, the first device of its kind to last a full year, for adults with Type 1 and Type 2 diabetes. 研发者是Senseonics和Ascensia Diabetes Care,每年只需要一次插入, 提高了方便性和准确性. Developed by Senseonics and Ascensia Diabetes Care, it requires only one insertion annually, improving convenience and accuracy. 该系统定于2024年底投入商业使用,并可能与用于自动运载系统的胰岛素泵集成。 The system is set for commercial release in late 2024 and may integrate with insulin pumps for automated delivery systems.